Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
16,761
Total Claims
$1.4M
Drug Cost
779
Beneficiaries
$1,809
Cost/Patient
Risk Score Breakdown 33/100
Score components are additive. Read full methodology
Peer Comparison vs. 44,021 Emergency Medicine providers
-96%
Opioid rate vs peers
0.4% vs 9.4% avg
+1016%
Brand preference vs peers
16.6% vs 1.5% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.4%
Opioid Rate
62
Opioid Claims
$4,040
Opioid Cost
22.6%
Long-Acting Rate
Brand vs Generic
Brand: 2,758 claims · $1.1M
Generic: 13,897 claims · $334K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 406 | $171K |
| Semaglutide | 85 | $98K |
| Rivaroxaban | 157 | $65K |
| Sitagliptin Phosphate | 55 | $58K |
| Fluticasone/Vilanterol | 92 | $44K |
| Dapagliflozin Propanediol | 43 | $44K |
| Sacubitril/Valsartan | 77 | $43K |
| Empagliflozin | 40 | $39K |
| Rifaximin | 36 | $33K |
| Budesonide/Formoterol Fumarate | 70 | $32K |
| Semaglutide | 22 | $30K |
| Fluticasone/Umeclidin/Vilanter | 32 | $30K |
| Insulin Glargine,hum.Rec.Anlog | 86 | $28K |
| Insulin Aspart | 29 | $27K |
| Linaclotide | 41 | $21K |
Prescribing Profile
Patient Profile
75
Avg Age
57%
Female
1.53
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About